Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Leukemia, Myeloid, Acute 25Myelodysplastic Syndromes 8Advanced Solid Tumors 8Myeloproliferative Disorders 5Leukemia, Myelomonocytic, Chronic 5Ovarian Neoplasms 4Neoplasms 4Multiple Myeloma 4Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Advanced Solid Tumour 4Advanced Solid Tumor 4Small Cell Lung Carcinoma 3Recurrence 3Leukemia, Monocytic, Acute 3Triple Negative Breast Neoplasms 2Thrombocythemia, Essential 2Squamous Cell Carcinoma of Head and Neck 2Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Neoplasm Metastasis 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelomonocytic, Acute 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Biliary Tract Neoplasms 2Advanced Malignant Solid Tumor 2Advanced Lung Cancer 2

Interventions

Dexamethasone 116daratumumab 68Lenalidomide 67Bortezomib 55pomalidomide 45carfilzomib 40Cyclophosphamide 33Calcium Dobesilate 32Specimen Handling 30Biopsy 28Magnetic Resonance Spectroscopy 25isatuximab 20belantamab mafodotin 20talquetamab 17iberdomide 17fludarabine 17Melphalan 15dexamethasone acetate 14dexamethasone 21-phosphate 14auricularum 14fludarabine phosphate 11selinexor 10elotuzumab 10tocilizumab 9X-Rays 8Nivolumab 8trametinib 7Sirolimus 7Whole-Body Irradiation 6Mycophenolic Acid 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Multiple Myeloma × Injections × 90 days × Clear all
NCT07623798 2026-06-03

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Not yet recruiting
255 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT07085728 2026-05-15

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
74 enrolled
Plasma cell

Multiple Myeloma

NCT05020236 2026-05-05

MAGNETISMM-5

Pfizer

Phase 3 Recruiting
944 enrolled
Plasma cell

Multiple Myeloma

NCT06484777 2026-04-16

A Clinical Study of SHR-9539 in Patients With Multiple Myeloma

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1 Recruiting
138 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡